MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from the Phase 3 SOPHIA study comparing margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer who…

Read the full article here

Source: www.oncologytube.com

Categories: Hem/Onc News and Journals

Tweets with this article

Oncology Tube

MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium https://t.co/rgBvIyZWHE https://t.co/5Qh5R0aH1n

Breast Cancer Treatment: No Radiation Needed Post-Chemo?

New breast cancer treatment study shows no need for radiation after chemo success. Learn how this changes care.

Oncology Tube July 15, 2025

2025 Breast Cancer Treatment: I-SPY2 Trial’s Lobular Chemotherapy Breakthrough

Explore the 2025 I-SPY2 Trial’s breakthrough in breast cancer treatment for lobular carcinoma and MammaPrint improve outcomes.

Oncology Tube July 14, 2025

Home: Cell Press

Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron,…

Oncology Tube July 11, 2025

Post-CDK4/6 Inhibitor Treatment: Guide to HR+/HER2- MBC

Guide to post-CDK4/6 inhibitor treatment for HR+/HER2- breast cancer. Learn resistance, therapies, and access with ASCO expertise.

Oncology Tube June 23, 2025

MATTERHORN Trial: Durvalumab Improves EFS in Gastric Cancer

Discover insights from the MATTERHORN trial, showcasing the impact of durvalumab combined with FLOT chemotherapy.

Oncology Tube June 20, 2025

New FDA Voucher Program: How It Impacts Oncology Drug Approvals

See how the FDA’s new voucher program impacts oncology drug approvals, focusing on speed and safety. Tailored for ASCO.org viewers.

Oncology Tube June 20, 2025

New FDA Voucher Program: How It Impacts Oncology Drug Approvals

See how the FDA’s new voucher program impacts oncology drug approvals, focusing on speed and safety. Tailored for ASCO.org viewers.

Oncology Tube June 19, 2025

HR+/HER2- MBC 2L Outcomes: Top 10 ASCO 2025 Breakthroughs

Explore HR+/HER2- metastatic breast cancer 2L outcomes with crucial insights from ASCO 2025 on median progression-free survival.

Oncology Tube June 18, 2025

Bispecific Antibodies Cancer Therapy: 2025 Advances

Discover BsAb oncology & 2025 clinical trials. Explore bispecific antibodies cancer therapy on OncologyTube.com. Watch now!

Oncology Tube June 17, 2025

China Leads Oncology Trials with 39% Share | OncologyTube

Explore how China oncology trials are revolutionizing cancer research with a remarkable increase in clinical trials.

Oncology Tube June 16, 2025

Related Articles